	Multiple sclerosis
Argumentative policy analysis
Interferon-beta
Interactive policy development
Participatory workshops
	central pre-utilisation approval
actors
target populations
problems
clinical trials
neurologists
HCIB
reimbursement requests
policy
workshops
patients
Health
Ministry
guideline
criteria
target groups
drug
national database
participants
treatment
PAM
interactive process
national registry
medical advisor
costs
long-term effectiveness
Policy Development Process
smaller
drug interferon-beta
database
clinical practice
interventions
theories
central committee
order
development
conduct a re-appraisal
data
limited
effective
specific recommendations
high
clear protocol
measures
relevant
lower
reimbursement
normative
variables

